Abstract:Gastric cancer, a common and severe malignancy, is associated with unfavorable outcomes and limited therapeutic options. The exploration of the potential link between plasma histone-modifying enzymes and gastric cancer through Mendelian randomization (MR) analysis offers an opportunity to identify new therapeutic targets and biomarkers. In this study, data on plasma histone-modifying enzymes were obtained from the International Working Unit Open genome-wide association studies project, and summary statistics of gastric cancer from the FinnGen study were analyzed. Forward and inverse MR were performed to determine the causal relationship between plasma histone-modifying enzymes and gastric cancer. The principal methodology for MR is the inverse variance weighted (IVW) method. Additionally, a sensitivity analysis was performed to determine the robustness of the findings. Finally, bioinformatics was used for the preliminary functional analysis. Our forward MR analysis revealed that the plasma Set1/Ash2 histone methyltransferase complex subunit ASH2 (ASH2L) was positively associated with gastric cancer risk, and the histone-lysine N-methyltransferase SETMAR (SETMAR) was negatively associated. Inverse MR analysis revealed that gastric cancer incidence was negatively correlated with the expression of plasma histone acetyltransferase KAT6A (KAT6A). These findings were consistent across different statistical methods and were deemed unlikely to have been distorted by horizontal pleiotropy. Furthermore, bioinformatics analysis indicated that ASH2L, SETMAR, and KAT6A are differentially expressed in various tumors and are significantly correlated with both the prognosis of gastric cancer and the infiltration of various immune cells. Thus, plasma histone-modifying enzymes may be causally linked to gastric cancer, and ASH2L, SETMAR, and KAT6A could play crucial roles as biomarkers and therapeutic targets in managing gastric cancer.

Advances in Study on Histone Modification in Gastric Cancer

Recent Advance of Histone Modification in Gastric Cancer : A Review

Interaction of ncRNA and Epigenetic Modifications in Gastric Cancer: Focus on Histone Modification

Research Progress on Oncogene, Suppressor Gene andtheir Products in Gastric Carcinoma

Advances in Clinical and Pathological Diagnosis of Chronic Gastritis

Recent Progress in the Study of Methylated Tumor Suppressor Genes in Gastric Cancer

Epigenetic Biomarkers: Potential Applications in Gastrointestinal Cancers.

Epigenetic Variation Analysis Leads to Biomarker Discovery in Gastric Adenocarcinoma

Epigenetic modifications involving ncRNAs in digestive system cancers: focus on histone modification

Relationship between histone demethylase LSD family and development and prognosis of gastric cancer

Altered 5-Hydroxymethylcytosine Landscape in Primary Gastric Adenocarcinoma

Methylation Modification In Gastric Cancer And Approaches To Targeted Epigenetic Therapy

The Value of Epigenetics Changes in Human Gastric Cancer

Histone modifications in head and neck squamous cell carcinoma

Histone-modifying enzymes and gastric cancer: Search for potential biomarkers and therapeutic targets based on Mendelian randomization

Progress in Relationship Between EZH2 and Gastric Cancer

Progress and application of epitranscriptomic m6A modification in gastric cancer

Progress and Application of Epitranscriptomic M 6 A Modification in Gastric Cancer

Progress in the clinical research of gastric cancer

Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma

Interaction effects of DNA methylation and histone modification key enzymes in gastric cancer